Comments
Dr Reddy’s Laboratories Ltd has launched Vigabatrin Tablets, a therapeutic equivalent generic version of Sabril (vigabatrin) tablets approved by the US Food and Drug Administration (USFDA).
“We are pleased that this product has been designated as a Competitive Generic Therapy (CGT) by the FDA,” Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy’s Laboratories, said in a release on Tuesday.
Also read: Dr Reddy’s plans to roll out Covid vaccine Sputnik V in India in March
“With a CGT designation, we have 180-day CGT exclusivity to market this product,” he added.
The Sabril brand and generic had US sales of approximately $141 million MAT for the most recent 12 months ending in December 2020, according to IMS Health.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.